Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man.
The pharmacokinetics of the antiarrhythmic drug diprafenone have been investigated in 6 healthy volunteers following single intravenous (50 mg) and oral doses (50 and 150 mg). Diprafenone was mainly eliminated by metabolism in the liver. Following i.v. infusion of 50 mg diprafenone, the terminal half-life of elimination was 1.50 h, the volume of distribution at steady-state was 1.23 l.kg-1, and the free fraction in plasma was 1.68%. Mean total plasma clearance was 741 ml.min-1.70 kg-1, which approaches normal liver blood flow after correction for the blood/plasma concentration ratio. Thus, diprafenone can be classified as a high extraction drug. Following oral administration, a dose-dependent increase in bioavailability from 10.9 (50 mg dose) to 32.5% (150 mg dose) was observed. The data suggest that diprafenone is subject to saturable hepatic first-pass metabolism.
Trenk
D
D
Abteilung für Klinische Pharmakologie, Benedikt Kreutz Rehabilitationszentrum, Bad Krozingen, Federal Republic of Germany.
Wagner
F
F
Sachs
W
W
Jähnchen
E
E
D000284:Administration, Oral; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics*; D001682:Biological Availability; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D011405:Propafenone / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
D000889:Anti-Arrhythmia Agents; C047546:diprafenone; D011405:Propafenone